References

Current approaches to the management of brain metastases

10.1038/s41571-019-0320-3 · 2020 · External reference

Brain metastases: a society for neuro-oncology (SNO) consensus review on current management and future directions

10.1093/neuonc/noac118 · 2022 · External reference

Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives

10.1093/annonc/mdw532 · 2017 · External reference

Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study

10.1093/neuonc/nox077 · 2017 · External reference

The treatment of advanced melanoma: current approaches and new challenges

10.1016/j.critrevonc.2024.104276 · 2024 · External reference

CACHO (Central nervous system activity in cancer and hemato-oncologic diseases) network, real-world experience outcome in patients with central nervous system metastases: information on 2,226 patients during a 15-year period

10.1007/s11060-025-05190-y · 2025 · External reference

Management of brain metastases according to molecular subtypes

10.1038/s41582-020-0391-x · 2020 · External reference

Impact of brain metastases on quality of life and estimated life expectancy in patients with advanced non-small cell lung cancer

10.1016/j.jval.2014.08.2364 · 2014 · External reference

Leptomeningeal metastases from solid tumors: a society for neuro-oncology and American society of clinical oncology consensus review on clinical management and future directions

10.1093/neuonc/noae103 · 2024 · External reference

Analysis of prognostic factors and risk prediction in brain metastases: a SEER population-based study

10.3389/fonc.2025.1523069 · 2025 · External reference

Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets

10.1158/2159-8290.cd-15-0369 · 2015 · External reference

Emerging therapeutics and evolving assessment criteria for intracranial metastases in patients with oncogene-driven non-small-cell lung cancer

10.1038/s41571-023-00808-4 · 2023 · External reference

DESTINY-Breast12 study group, trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial

10.1038/s41591-024-03261-7 · 2024 · External reference

Tucatinib vs placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-positive metastatic breast cancer in patients with brain metastases: updated exploratory analysis of the HER2CLIMB randomized clinical trial

10.1001/jamaoncol.2022.5610 · 2023 · External reference

Post hoc analysis of lorlatinib intracranial efficacy and safety in patients with ALK-positive advanced Non–small-cell lung cancer from the phase III CROWN study

10.1200/jco.21.02278 · 2022 · External reference

Combined nivolumab and ipilimumab in Melanoma metastatic to the brain

10.1056/nejmoa1805453 · 2018 · External reference

Brain metastasis

10.1038/s41568-019-0220-y · 2020 · External reference

Liquid biopsy: creating opportunities in brain space

10.1038/s41416-023-02446-0 · 2023 · External reference

Assessing the clinical utility of liquid biopsies across 5 potential indications from therapy selection to population screening: a review

10.1001/jamainternmed.2023.3603 · 2023 · External reference

US food and drug administration approval summary: elacestrant for Estrogen Receptor-positive, human epidermal growth factor receptor 2-Negative, ESR1-Mutated advanced or metastatic breast cancer

10.1200/jco.23.02112 · 2024 · External reference

US food and drug administration approval summary: capivasertib with fulvestrant for hormone Receptor-positive, human epidermal growth factor receptor 2-Negative locally advanced or metastatic breast cancer with PIK3CA/AKT1/PTEN alterations

10.1200/jco.24.00427 · 2024 · External reference

Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges

10.1038/s41416-022-01776-9 · 2022 · External reference

Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology

10.1038/s41698-025-00876-y · 2025 · External reference

The coming of age of liquid biopsy in neuro-oncology

10.1093/brain/awad195 · 2023 · External reference

Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma

10.1038/ncomms9839 · 2015 · External reference

10.1186/s12916-022-02595-8

10.1186/s12916-022-02595-8 · 2022 · External reference

Cerebrospinal fluid circulating tumor DNA profiling for risk stratification and matched treatment of central nervous system metastases

10.1038/s41591-025-03538-5 · 2025 · External reference

BrainStorm: a multicenter international study to tackle CNS metastases in solid tumors

10.1038/s41591-023-02595-y · 2023 · External reference

Evaluating cancer of the central nervous system through next-generation sequencing of cerebrospinal fluid

10.1200/jco.2016.66.6487 · 2016 · External reference

Minimum technical preanalytical, patient, and clinical context data elements for cerebrospinal fluid liquid biopsy: recommendations for public database submissions

10.1200/po-24-00921 · 2025 · External reference

Genomic characterization of metastatic breast cancers

10.1038/s41586-019-1056-z · 2019 · External reference

Breast cancer brain metastases genomic profiling identifies alterations targetable by immune-checkpoint and PARP inhibitors

10.1038/s41698-024-00761-0 · 2024 · External reference

High frequency of complex TP53 mutations in CNS metastases from breast cancer

10.1038/bjc.2011.464 · 2012 · External reference

TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance

10.1158/1078-0432.ccr-13-2943 · 2014 · External reference

Genomic profiling and pre-clinical modelling of breast cancer leptomeningeal metastasis reveals acquisition of a lobular-like phenotype

10.1038/s41467-023-43242-x · 2023 · External reference

Meta-analysis of commonly mutated genes in leptomeningeal carcinomatosis

10.7717/peerj.15250 · 2023 · External reference

Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations

2017 · External reference

Discordance of PIK3CA and TP53 mutations between breast cancer brain metastases and matched primary tumors

10.1038/s41598-021-02903-x · 2021 · External reference

Cerebrospinal fluid circulating tumor DNA depicts profiling of brain metastasis in NSCLC

10.1002/1878-0261.13357 · 2023 · External reference

Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases

10.1093/annonc/mdy544 · 2019 · External reference

Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer

10.1038/s41467-022-35245-x · 2022 · External reference

Longitudinal shifts of solid tumor and liquid biopsy sequencing concordance in metastatic breast cancer

2022 · External reference

Quantification of cerebrospinal fluid tumor DNA in lung cancer patients with suspected leptomeningeal carcinomatosis

10.1038/s41698-024-00582-1 · 2024 · External reference

Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy

10.1093/annonc/mdy009 · 2018 · External reference

Epigenetic profiling for the molecular classification of metastatic brain tumors

10.1038/s41467-018-06715-y · 2018 · External reference

Prediction of brain metastasis development with DNA methylation signatures

10.1038/s41591-024-03286-y · 2025 · External reference